Redhill Biopharma (NASDAQ: RDHL)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-25 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.230 | -0.300 | -0.0700 | ||||
REV | 24.300M | 18.236M | -6.064M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Redhill Biopharma (NASDAQ: RDHL) through any online brokerage.
Other companies in Redhill Biopharma’s space includes: Opiant Pharma (NASDAQ:OPNT), SCYNEXIS (NASDAQ:SCYX), Terns Pharma (NASDAQ:TERN), Lipocine (NASDAQ:LPCN) and Longboard Pharmaceuticals (NASDAQ:LBPH).
The latest price target for Redhill Biopharma (NASDAQ: RDHL) was reported by HC Wainwright & Co. on Wednesday, September 15, 2021. The analyst firm set a price target for 21.00 expecting RDHL to rise to within 12 months (a possible 2023.14% upside). 2 analyst firms have reported ratings in the last year.
The stock price for Redhill Biopharma (NASDAQ: RDHL) is $0.9891 last updated August 10, 2022, 8:00 PM UTC.
There are no upcoming dividends for Redhill Biopharma.
Redhill Biopharma’s Q2 earnings are confirmed for Thursday, August 25, 2022.
There is no upcoming split for Redhill Biopharma.
Redhill Biopharma is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.